Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
Research and regulatory collaboration between Canadian biotechs Red Light Holland (OTCQB:TRUFF) and PharmAla (OTC:MDXXF) is bearing fruit. The partners are moving forward with a new project to bring Active Pharmaceutical Ingredient (API) extraction from Red Light's psilocybin truffles to a commercial manufacturing scale.
加拿大生物技術公司Red Light Holland（OTCQB: TRUFF）和PharMala（場外交易代碼：MDXXF）之間的研究和監管合作正在取得成果。合作伙伴正在推進一個新項目，將從Red Light的psilocybin松露中提取的活性藥物成分（API）推向商業生產規模。
An Ontario-based company producing, growing and selling functional mushrooms and mushroom home-grow kits in North America and Europe and premium psilocybin truffles in the Netherlands, Red Light Holland (RLH) recently hired MDXX-class molecules developer PharmAla for a one-year collaboration to seek regulatory approval for selling standardized doses of natural psilocybin products to clinical trials, government-approved access programs and emerging markets.
Red Light Holland（RLH）是一家總部位於安大略省的公司，在北美和歐洲生產、種植和銷售功能性蘑菇和蘑菇本土種植套件，並在荷蘭生產、種植和銷售優質迷幻藥松露。該公司最近聘請了MDX級分子開發商PharMala進行爲期一年的合作，尋求監管部門的批准，向臨床試驗、政府批准的准入計劃和新興市場銷售標準劑量的天然迷幻藥產品。
The experimental research on psilocybin truffles and API extraction will be managed by PharmAla researchers. The study is expected to yield "a process for the extraction and subsequent purification of psilocybin into a form such that it can be formulated into medical products for use in a variety of markets."
關於迷幻藥松露和API提取的實驗研究將由PharMala的研究人員管理。預計該研究將產生 “一種將迷幻藥提取並隨後純化爲一種可以將其配製成用於各種市場的醫療產品的方法。”
The psilocybin truffles recently imported to Canada through RLH's partner CCrest Labs will serve as starting material for the process development, which aims to be specific and standardized to enable its transfer to several facilities, for "full-scale" GMP manufacturing.
最近通過RLH的合作伙伴CCrest Labs進口到加拿大的psilocybin松露將作爲工藝開發的起始材料，該工藝旨在實現具體和標準化，以便將其轉移到多個工廠，用於 “全面的” GMP製造。
"While we have seen excellent movement in a number of emerging markets, it has become clear that there is also a demand for a range of medical products based off of psilocybin mushrooms and truffles and optionality is key in our two-pronged approach," explained Red Light Holland CEO and director Todd Shapiro.
Red Light Holland首席執行官兼董事託德·夏皮羅解釋說：“儘管我們在許多新興市場看到了良好的發展，但很明顯，對一系列基於迷幻藥蘑菇和松露的醫療產品的需求也很大，可選性是我們雙管齊下的關鍵。”
With this in mind, developing a process to manufacture natural-source psilocybin API would enable RLH "to produce high-margin psilocybin medical products – and gain valuable intellectual property," Shapiro added.
夏皮羅補充說，考慮到這一點，開發一種製造天然來源的迷幻藥API的工藝將使RLH “能夠生產高利潤的迷幻藥醫療產品，並獲得寶貴的知識產權”。
Photo: Benzinga edit with photo by geralt and sergeitokmakov on Pixabay.
照片：本辛加在 Pixabay 上用傑拉特和謝爾蓋托克馬科夫的照片進行編輯。
譯文內容由第三人軟體翻譯。